About ELAV-like protein 3
ELAV-like protein 3 (ELAVL3) is a protein
from Homo sapiens identified by UniProt accession
Q14576, 367 residues long.
MolForge cross-references it against 0 known binders and
135 disease associations.
Target properties
| Protein name | ELAV-like protein 3 |
| UniProt accession | Q14576 |
| Gene | ELAVL3 |
| Organism | Homo sapiens |
| Length | 367 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (135)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.46
- diastolic blood pressure · score 0.13
- generalised epilepsy · score 0.09
- autism spectrum disorder · score 0.09
- juvenile myoclonic epilepsy · score 0.09
- Generalized epilepsy with febrile seizures-plus · score 0.09
- temporal lobe epilepsy · score 0.08
- benign occipital epilepsy · score 0.08
- childhood absence epilepsy · score 0.08
- autosomal dominant epilepsy with auditory features · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q14576-F1 | alphafold | PREDICTED | 75.49 | — |
Amino-acid sequence (367 residues)
MVTQILGAME SQVGGGPAGP ALPNGPLLGT NGATDDSKTN LIVNYLPQNM TQDEFKSLFG SIGDIESCKL VRDKITGQSL GYGFVNYSDP NDADKAINTL NGLKLQTKTI KVSYARPSSA SIRDANLYVS GLPKTMSQKE MEQLFSQYGR IITSRILVDQ VTGVSRGVGF IRFDKRIEAE EAIKGLNGQK PLGAAEPITV KFANNPSQKT GQALLTHLYQ SSARRYAGPL HHQTQRFRLD NLLNMAYGVK SPLSLIARFS PIAIDGMSGL AGVGLSGGAA GAGWCIFVYN LSPEADESVL WQLFGPFGAV TNVKVIRDFT TNKCKGFGFV TMTNYDEAAM AIASLNGYRL GERVLQVSFK TSKQHKA
Explore ELAV-like protein 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets